---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-027012"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T08:56:35.375152+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Q2 2024 net loss $2.3M, cash $50.9M; DLB trial enrolled, topline Dec 2024

## Summary
- Net loss $2.3M in Q2 2024 vs $1.4M in Q2 2023; operating loss $3.0M vs $1.2M.
- Cash, equivalents and marketable securities $50.9M at June 30, 2024, up from $7.8M at Dec 31, 2023.
- Completed enrollment in Phase 2b RewinD-LB trial (neflamapimod for early-stage DLB) in June 2024; topline data expected Dec 2024.
- Private placement in April 2024 raised $50M upfront, with potential total proceeds up to $149.4M.
- NIA grant revenue $5.6M for H1 2024 vs $3.1M for H1 2023; cash runway extended through 2025.

## SEC filing metadata
- accession: 0001437749-24-027012
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924027012/0001437749-24-027012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924027012/crvo20240815_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-027012
- JSON: https://secwatch.observer/filing/0001437749-24-027012.json
- Plain text: https://secwatch.observer/filing/0001437749-24-027012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.